TABLE 1

Lefamulin in vitro activity and cumulative MIC distributions against the overall population of S. pneumoniae selected serotypes and resistance subsets

Serotypea (no. tested/%)MIC (μg/ml)No. of isolates (cumulative %)b inhibited at a lefamulin MIC (μg/ml) of:
50%90%≤0.0150.030.060.120.250.51
All (822)0.120.257 (0.9)24 (3.8)149 (21.9)363 (66.1)237 (94.9)39 (99.6)3 (99.9)
    19A (123/15.0)0.120.252 (1.6)3 (4.1)28 (26.8)60 (75.6)24 (95.1)5 (99.2)1 (100.0)
    3 (70/8.5)0.060.120 (0.0)2 (2.9)40 (60.0)26 (97.1)2 (100.0)
    35B (54/6.6)0.120.250 (0.0)0 (0.0)4 (7.4)28 (59.3)21 (98.1)1 (100.0)
    6C/6D (53/6.4)0.120.250 (0.0)4 (7.5)9 (24.5)25 (71.7)13 (96.2)2 (100.0)
    22A/22F (48/5.8)0.120.250 (0.0)0 (0.0)2 (4.2)24 (54.2)22 (100.0)
    11A/11D (47/5.7)0.250.50 (0.0)0 (0.0)2 (4.3)13 (31.9)24 (83.0)8 (100.0)
    15A/15F (45/5.5)0.120.251 (2.2)0 (2.2)4 (11.1)21 (57.8)18 (97.8)1 (100.0)
    7F (45/5.5)0.120.250 (0.0)0 (0.0)2 (4.4)31 (73.3)12 (100.0)
    15B/15C (39/4.7)0.120.250 (0.0)2 (5.1)6 (20.5)17 (64.1)13 (97.4)1 (100.0)
    19F (24/2.9)0.120.252 (8.3)1 (12.5)2 (20.8)13 (75.0)5 (95.8)1 (100.0)
    Otherc (274/33.3)0.120.252 (0.7)12 (5.1)50 (23.4)105 (61.7)83 (92.0)20 (99.3)2 (100.0)
Resistance phenotyped
    ERY-nonsusceptible (305/37.1)0.120.254 (1.3)7 (3.6)50 (20.0)143 (66.9)89 (96.1)9 (99.0)3 (100.0)
    ERY-susceptible (517/62.9)0.120.253 (0.6)17 (3.9)99 (23.0)220 (65.6)148 (94.2)30 (100.0)
    CRO-nonsusceptible (61/7.4)0.120.251 (1.6)2 (4.9)12 (24.6)33 (78.7)13 (100.0)
    CRO-susceptible (761/92.6)0.120.256 (0.8)22 (3.7)137 (21.7)330 (65.0)224 (94.5)39 (99.6)3 (100.0)
    MDR (180/21.9)0.120.254 (2.2)6 (5.6)34 (24.4)83 (70.6)48 (97.2)3 (98.9)2 (100.0)
    Non-MDR (642/78.1)0.120.253 (0.5)18 (3.3)115 (21.2)280 (64.8)189 (94.2)36 (99.8)2 (100.0)
  • a The 13-valent conjugate vaccine contains coverage against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

  • b Modal MIC values are in bold.

  • c This category comprises 28 serotypes including those that are nontypeable.

  • d Erythromycin (ERY)-nonsusceptible and -susceptible groups include isolates with MIC values of ≥0.5 and ≤0.25 μg/ml, respectively (CLSI criteria). Ceftriaxone (CRO)-nonsusceptible and -susceptible groups include isolates with MIC values of ≥2 and ≤1 μg/ml, respectively (CLSI criteria). MDR, multidrug resistant (i.e., isolates displaying resistance phenotype to at least three drug classes); the MDR subset includes the following serotypes/serogroups (no.): 19A (81), 15A/F (42), 15B/15C (10), 19F (11), nontypeable (7), 6C/6D (5), 23A (5), 3 (3), 9N/9L (3), 23F (3), 14 (3), 35B (2), 21 (1), 22F/22A (1), 6A (1), 7F (1), and 34 (1).